FOLFIRI (Irinotecan, 5-Fluorouracil, and Leucovorin)

DRUG2 trials

Sponsors

Sanofi, SCRI Development Innovations, LLC

Conditions

Colon CancerColorectal CancerColorectal Cancer (CRC)Colorectal NeoplasmsNeoplasm MetastasisRectal Cancer

Phase 2

A Study of Fruquintinib Plus FOLFIRI as Second-Line Treatment for Participants With Metastatic Colorectal Cancer (mCRC)

RecruitingNCT07011576

SCRI Development Innovations, LLCColon Cancer, Colorectal Cancer, Colorectal Cancer (CRC) +1

Start: 2025-09-29End: 2027-06-01Target: 60Updated: 2026-03-18

Phase 3

Aflibercept Versus Placebo in Combination With Irinotecan and 5-FU in the Treatment of Patients With Metastatic Colorectal Cancer After Failure of an Oxaliplatin Based Regimen

CompletedNCT00561470

SanofiColorectal Neoplasms, Neoplasm Metastasis

Start: 2007-11-30End: 2012-06-30Updated: 2012-09-28

Related Papers

Exploratory biomarker analysis of RAS/BRAF somatic mutations and gene expression signatures for predicting treatment effects of aflibercept in the velour trial.

2026-01-13

Deep learning for the prediction of early on-treatment response in metastatic colorectal cancer from serial medical imaging.

2021-11-1754 citations

Protocol of the EFFORT study: a prospective study of FOLFIRI plus aflibercept as second-line treatment after progression on FOLFOXIRI plus bevacizumab or during maintenance treatment in patients with unresectable/metastatic colorectal cancer

BMC Cancer2020-11-174 citations

Safety and Effectiveness of Aflibercept + Fluorouracil, Leucovorin, and Irinotecan (FOLFIRI) for the Treatment of Patients with Metastatic Colorectal Cancer (mCRC) in Current Clinical Practice: OZONE Study

Cancers2020-03-1115 citations

Phase II trial of aflibercept with FOLFIRI as a second-line treatment for Japanese patients with metastatic colorectal cancer.

2019-02-2232 citations

Observed benefit and safety of aflibercept in elderly patients with metastatic colorectal cancer: An age-based analysis from the randomized placebo-controlled phase III VELOUR trial.

2017-08-1228 citations

Velour trial biomarkers update: Impact of RAS, BRAF, and sidedness on aflibercept activity.

Journal of Clinical Oncology2017-05-2056 citations

European Medicines Agency approval summary: Zaltrap for the treatment of patients with oxaliplatin-resistant metastatic colorectal cancer.

2017-05-0212 citations

Placental growth factor and the angiogenic environment based on analysis of baseline plasma biomarkers from the VELOUR trial.

Journal of Clinical Oncology2017-02-018 citations

A phase II study of ziv-aflibercept (Z) + FOLFIRI in Japanese patients (pts) with metastatic colorectal cancer (mCRC).

Journal of Clinical Oncology2017-02-013 citations

Aflibercept Plus FOLFIRI vs. Placebo Plus FOLFIRI in Second-Line Metastatic Colorectal Cancer: a Post Hoc Analysis of Survival from the Phase III VELOUR Study Subsequent to Exclusion of Patients who had Recurrence During or Within 6 Months of Completing Adjuvant Oxaliplatin-Based Therapy.

2016-06-0126 citations

A retrospective comparison of the ability of lesion volumes and longest diameters to predict clinical outcome in metastatic colorectal cancer.

Journal of Clinical Oncology2015-05-20

The consistency of effect of ziv-aflibercept (Z) in the bevacizumab (B) pre-treated subgroup of patients (pts) in the velour trial stratified by first-line progression ≥ 9 months (mos) versus < 9 mos.

Journal of Clinical Oncology2014-05-203 citations

A preclinical and clinical review of aflibercept for the management of cancer.

2012-01-2081 citations